Theravance Biopharma Inc

TBPH

$16.9

-2.56% (1 year change)

Avg closing price

Price range

Market Cap

$1.1 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

$-62.9 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-4.73

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-3.64x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-72.2 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

316

The number of full time employees.

Revenue & Earnings

Balance Sheet

Theravance Biopharma Inc

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

News

Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference

Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference

DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of org...

PR Newswire PR Newswire, 10 days ago
Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, ...

PR Newswire PR Newswire, 21 days ago
Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 5.3%

Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 5.3%

Theravance Biopharma Inc (NASDAQ:TBPH) traded up 5.3% during mid-day trading on Thursday . The company traded as high as $19.13 and last traded at $19.03. 258,232 shares were traded during mid-day ...

The Olympia Report The Olympia Report, about 1 month ago